Background: Cyathocline purpurea
is known for its traditional therapeutic potential in Asian countries. However, limited reports are available on its anticancer activity and phytochemical analysis. Objective:
The aim of the present study was to investigate anticancer activity and phytochemical analysis of C. purpurea
isolation, identification, characterisation and quantification of an active constituent. Methods:
MTT assay was performed to check cytotoxicity of extract in a panel of human cancer cell lines along with non-cancerous human peripheral blood mononuclear cells (PBMCs). To elucidate phytochemicals responsible for anti-proliferative activity, we did phytochemicals analysis of the pet-ether extract by UPLC-ESI-QTOF/MS, MS/MS, and FTIR. Further isolation of an active constituent was carried out by repeated column chromatography coupled with thin layer chromatography. And their purity was assessed using UV-VIS, IR, 1
CNMR, DEPT, and mass spectra. Further, compound was quantified using HPLC. Result:
Pet-ether extract showed IC50
values such as 73.99, 62.59 and 62.51 μg/ml against MDA-MB-231, MCF-7, and KB cell lines respectively. It is found to be more effective in NCI-H23 cell line with IC50
value of 26.11μg/ml whereas a lowest inhibition was seen in MDA-MB-453 cell line with IC50
of 83.97μg/ml. Several compounds belonging to Terpenes, Phenolic and aromatic, Fatty acids and amides, Steroids groups were identified. The yield of isolated active compound: 6α-hydroxy-4, 10-guainadien-8β,12-olide (SRCP1) was found to be 289.9246 µg/mg of pet-ether extract. It showed IC50
value 9.98 µg/ml in NCI-H23 cell line. The SRCP1 showed better anti-migration potential than the standard drug actinomycin D in non-small cell lung cancer cells.Conclusion:
Pet-ether extract showed anticancer activity towards cancer cells associated phytochemicals were identified from C. purpurea.
The active compound SRCP1 was isolated purified and characterised by spectroscopic analysis and assessed for anticancer activity.